Creative Medical Technology Holdings Congratulates 2025 Nobel Laureates for Regulatory T Cell Breakthroughs
Creative Medical (NASDAQ: CELZ) announced receipt of two U.S. patents for its ImmCelz™ regulatory T cell platform and congratulated the 2025 Nobel laureates for Treg discoveries. The company named U.S. Patent 12931925B2 (expires 2043-05-24) for prevention/treatment of Type 1 diabetes via myeloid suppressor cell augmentation, and U.S. Patent 12385011B2 (expires 2042-12-15) for treating heart failure and post-infarct remodeling using ex vivo reprogrammed immune cells. Creative Medical said ImmCelz™ uses "supercharged" regulatory T cells, is being evaluated in the ongoing CREATE-1 clinical trial, and targets a U.S. treatable heart failure population of over 5 million and >b>6 million refractory angina candidates.
The release positions these patents as IP protection through 2042–2043 and highlights the company’s aim to translate Treg biology into regenerative immunotherapies.
Creative Medical (NASDAQ: CELZ) ha annunciato di aver ricevuto due brevetti statunitensi per la sua piattaforma di cellule T regolatorie ImmCelz™ e ha rivolto congratulazioni ai vincitori del Nobel 2025 per le scoperte delle Treg. L’azienda ha indicato la Brevetto USA 12931925B2 (scadenza 24-05-2043) per la prevenzione/trattamento del diabete di tipo 1 tramite l’aumento delle cellule mieloidi soprattutto immunitarie, e la Brevetto USA 12385011B2 (scadenza 15-12-2042) per trattare l’insufficienza cardiaca e la rimodellizzazione post-infarto mediante cellule immunitarie esa es vivo riprogrammate. Creative Medical ha dichiarato che ImmCelz™ utilizza cellule T regolatorie “supercaricate”, è in valutazione nel trial clinico in corso CREATE-1 e punta a una popolazione statunitense di insufficienza cardiaca trattabile di oltre 5 milioni e oltre 6 milioni di candidati con angina refrattaria.
Il comunicato posiziona questi brevetti come protezione IP fino al 2042–2043 e mette in risalto l’obiettivo dell’azienda di tradurre la biologia delle Treg in immunoterapie rigenerative.
Creative Medical (NASDAQ: CELZ) anunció la recepción de dos patentes estadounidenses para su plataforma de células T reguladoras ImmCelz™ y felicitó a los laureados del Nobel 2025 por los descubrimientos de Treg. La empresa nombró la Patente de EE. UU. 12931925B2 (vence 24-05-2043) para la prevención/tratamiento de la diabetes tipo 1 mediante la augmentación de células supresoras mieloides, y la Patente de EE. UU. 12385011B2 (vence 15-12-2042) para tratar la insuficiencia cardíaca y la remodelación posinfarto usando células inmunes reprogramadas ex vivo. Creative Medical dijo que ImmCelz™ utiliza células T reguladoras “súper cargadas”, se está evaluando en el ensayo clínico en curso CREATE-1, y apunta a una población estadounidense con insuficiencia cardíaca tratable de más de 5 millones y más de 6 millones de candidatos con angina refractaria.
El comunicado sitúa estas patentes como protección de propiedad intelectual hasta 2042–2043 y destaca el objetivo de la empresa de traducir la biología de Treg en inmunoterapias regenerativas.
Creative Medical (NASDAQ: CELZ)가 ImmCelz™ 규제 T 세포 플랫폼에 대한 두 건의 미국 특허를 수령했다는 소식을 발표하고, 2025년 노벨상 수상자들의 Treg 발견을 축하했습니다. 이 회사는 당뇨병 제1형의 예방/치료를 위한 골수 억제 세포 증강으로의 미국 특허 12931925B2의 만료기간을 2043-05-24로 명시했고, 손상 후 재형성 및 심부전 치료를 위한 체외 재프로그램된 면역세포를 이용하는 미국 특허 12385011B2의 만료기간을 2042-12-15로 명시했습니다. Creative Medical는 ImmCelz™가 '초강력' 규제 T 세포를 사용하며 진행 중인 CREATE-1 연구에서 평가되고 있으며, 미국에서 치료 가능한 심부전 인구가 5백만 명 이상, 난치성 협착성 협심증 후보자도 6백만 명 이상에 이른다고 밝혔습니다.
이 발표는 이러한 특허를 2042~2043년까지의 IP 보호로 제시하고, Treg 생물학을 재생 면역요법으로 번역하려는 회사의 목표를 강조합니다.
Creative Medical (NASDAQ: CELZ) a annoncé la réception de deux brevets américains pour sa plateforme de cellules T régulatrices ImmCelz™ et a félicité les lauréats Nobel 2025 pour leurs découvertes sur les Treg. L’entreprise a nommé Brevet américain 12931925B2 (expira 24-05-2043) pour la prévention/le traitement du diabète de type 1 via l’augmentation des cellules suppressives myéloïdes, et le Brevet américain 12385011B2 (expire 15-12-2042) pour le traitement de l’insuffisance cardiaque et le remodelage post-infarctus en utilisant des cellules immunitaires reprogrammées ex vivo. Creative Medical a déclaré que ImmCelz™ utilise des cellules T régulatrices « surdimensionnées », est évalué dans l’essai clinique en cours CREATE-1 et vise une population américaine traitable pour l’insuffisance cardiaque de plus de 5 millions et plus de 6 millions de candidats à l’angine réfractaire.
Le communiqué positionne ces brevets comme une protection de propriété intellectuelle jusqu’en 2042–2043 et souligne l’objectif de l’entreprise de traduire la biologie des Treg en immunothérapies régénératives.
Creative Medical (NASDAQ: CELZ) gab bekannt, zwei US-Patente für seine ImmCelz™ regulierenden T-Zell-Plattform erhalten zu haben, und gratulierte den Nobelpreisträgern 2025 für Treg-Entdeckungen. Das Unternehmen nannte US-Patent 12931925B2 (läuft ab am 24.05.2043) zur Prävention/Behandlung von Typ-1-Diabetes durch die Steigerung myeloider suppressorischer Zellen, und US-Patent 12385011B2 (läuft ab am 15.12.2042) zur Behandlung von Herzinsuffizienz und postinfarkt REModellierung durch ex vivo umprogrammierte Immunzellen. Creative Medical sagte, ImmCelz™ verwende "supergeladene" regulatorische T-Zellen, wird im laufenden CREATE-1-Klinikversuch evaluiert und zielt auf eine in den USA behandelbare Herzinsuffizienzpopulation von über 5 Millionen sowie über 6 Millionen refraktärer Angina-Kandidaten ab.
Die Meldung positioniert diese Patente als IP-Schutz bis 2042–2043 und hebt das Ziel des Unternehmens hervor, die Treg-Biologie in regenerativ immuntherapeutische Ansätze zu übertragen.
Creative Medical (NASDAQ: CELZ) أعلنت عن استلامها لبراءتي اختراع أمريكيتين لمنصة الخلايا التنظيمية T ImmCelz™ وهنأت الفائزين بجائزة نوبل 2025 لاكتشافات Treg. حدّدت الشركة براءة الاختراع الأمريكية 12931925B2 (تنتهي صلاحيتها في 24-05-2043) للوقاية/العلاج لمرض السكري من النوع الأول عبر تعزيز الخلايا المثبطة النخاعية المِحورية، و براءة الاختراع الأمريكية 12385011B2 (تنتهي صلاحيتها في 15-12-2042) لعلاج الفشل القلبي وإعادة تشكيل ما بعد الاحتشاء باستخدام خلايا مناعية مُعاد برمجتها خارج الجسم. وقالت Creative Medical إن ImmCelz™ يستخدم خلايا T تنظيمية "مسلَّحة"، ويُقيَّم في التجربة السريرية الجارية CREATE-1، ويستهدف في الولايات المتحدة فئة من مرضى الفشل القلبي القابل للعلاج تفوق 5 ملايين، وأكثر من 6 ملايين من مرشحي الذبحة الصدرية المعندة.
تبرز النشرة هذه البراءات كحماية ملكية فكرية حتى 2042–2043 وتؤكد هدف الشركة في ترجمة بيولوجيا Treg إلى علاجات مناعية جدّية حيوية.
Creative Medical (NASDAQ: CELZ) 宣布获得用于其 ImmCelz™ 调控性 T 细胞平台的两项美国专利，并向2025年诺贝尔奖得主在 Treg 发现在化方面致以祝贺。公司将 美国专利 12931925B2（于 2043-05-24 到期）用于通过髓源抑制细胞的增强来预防/治疗1型糖尿病；将 美国专利 12385011B2（于 2042-12-15 到期）用于通过体外重新编程的免疫细胞治疗心力衰竭及梗死后重塑。Creative Medical 表示 ImmCelz™ 使用“超充电”的调控性 T 细胞，正在进行中的 CREATE-1 临床试验中评估，并且目标美国可治疗心力衰竭人群超过 500万及 600万以上的难治性冠心病候选人。
公告将这些专利定位为直至 2042–2043 年的知识产权保护，并强调公司将 Treg 生物学转化为再生免疫治疗的目标。
- Two U.S. patents issued: 12931925B2 and 12385011B2
- Patent expirations extend exclusivity to 2042–2043
- CREATE-1 clinical trial ongoing for Type 1 diabetes validation
- Addressable U.S. heart failure population cited as >5 million
- Press release contains no clinical efficacy results or outcome data from CREATE-1
- Patent terms expire by 2043, limiting long-term exclusivity
Insights
New U.S. patents for ImmCelz™ and alignment with ongoing clinical work strengthen Creative Medical's IP and program clarity.
Creative Medical received two U.S. patents covering its ImmCelz™ platform: U.S. Patent Number 12931925B2 (expires
Patents provide legally enforceable claims that can protect program-specific methods and compositions. The two issued patents extend protection into the early 2040s, which supports longer-term development planning. Key dependencies include claim scope breadth, prosecutorial or post-issuance challenges, and the ability to translate protected methods into reproducible, clinic-ready procedures.
Watch for concrete, monitorable items: publication of trial data from
Recent Issuance of U.S. Patents Covering ImmCelz™ — Supercharged Regulatory T Cell Programs in Heart Failure and Type 1 Diabetes Reinforce Creative Medical’s Similar Research Focus
PHOENIX, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”), a clinical-stage biotechnology company pioneering regenerative immunotherapy, today congratulated Mary E. Brunkow, Ph.D., Fred Ramsdell, Ph.D., and Shimon Sakaguchi, M.D., Ph.D. on being awarded the 2025 Nobel Prize in Physiology or Medicine for foundational discoveries in peripheral immune tolerance and the biology of regulatory T cells (Tregs). Their work—including the identification of Tregs and the central role of FOXP3—reshaped modern immunology and catalyzed new treatment strategies across autoimmunity, transplantation, and cancer.
In parallel with this global recognition of Treg science, Creative Medical reiterated that it has recently received two U.S. Patents for its proprietary ImmCelz™ platform: (1) U.S. Patent Number 12931925B2 (expires 2043-05-24) for the prevention and/or treatment of Type 1 Diabetes by augmentation of myeloid suppressor cell activity; and (2) U.S. Patent Number 12385011B2 (expires 2042-12-15) for the treatment of heart failure and/or post infarct pathological remodeling by ex vivo reprogrammed immune cells. Both of these programs utilize the Company's super charged Regulatory T cells.
“Today’s Nobel spotlight is squarely on Tregs—the same biology our ImmCelz™ engine is built to harness,” said Timothy Warbington, CEO of Creative Medical. “With dual patents spanning cardiometabolic disease, we believe Creative Medical is constructing an IP-fortified, category-defining regenerative immunotherapy franchise with runway to at least 2042. Our strategy is simple: translate Nobel-recognized immunology into disruptive, patient-centric procedures that may unlock durable value for patients, partners and shareholders alike.”
The Company’s heart failure allowance protects broad methods to treat patients at risk of, or with, heart failure and post-infarct pathological remodeling using the ImmCelz™ product, which is delivered via an ultra-minimally invasive outpatient procedure. In the United States alone, the treatable heart failure population exceeds five million, and more than six million patients with refractory angina may also be candidates—underscoring the potential scale of impact.
The Type 1 diabetes allowance supports a broad, cell-based immunotherapy approach—including supercharged T regulatory cells—and has been validated using cells from patients with Type 1 diabetes. This program aligns with the Company’s ongoing CREATE-1 clinical trial, further reinforcing Creative Medical’s focus on regenerative immunotherapy in autoimmune disease.
“Tregs are the immune system’s peacekeepers. The Nobel recognition amplifies decades of evidence that precise Treg modulation can recalibrate immunity,” Warbington added. “ImmCelz™ was engineered to reprogram a patient’s own immune cells outside the body, supercharge them with optimized cell-free factors, and re-introduce them—an approach designed to orchestrate repair, not just suppress symptoms. We see an expanding opportunity to deploy this platform across high-burden indications where immune over-activation and tissue damage intersect.”
About ImmCelz™
Creative Medical’s ImmCelz™ platform utilizes a patient’s own extracted immune cells that are then “reprogrammed/supercharged” by culturing them outside the body with optimized cell-free factors. The cells are then re-injected into the patient from whom they were extracted. The Company believes this process endows immune cells with regenerative properties on top of their innate functions, enabling potential treatment across multiple indications.
About Creative Medical Technology Holdings
Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) is a clinical-stage biotechnology company pioneering regenerative medicine solutions across multiple indications. The Company leverages cutting-edge cell therapy technologies to develop transformative treatments aimed at improving patient outcomes.
Forward-Looking Statements
This news release may contain forward-looking statements, including, but not limited to, statements regarding the development and commercialization of the Company’s therapies (including ImmCelz™), market opportunities, clinical progress, strategic alternatives, and the strength of the Company’s intellectual property portfolio. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks and uncertainties are detailed in the Company’s periodic reports filed with the U.S. Securities and Exchange Commission (SEC) and available at www.sec.gov. The Company undertakes no obligation to update forward-looking statements except as required by law.
Nobel Prize® is a registered trademark of the Nobel Foundation; use herein is for identification only and does not imply any affiliation or endorsement.
| Contact: | |
| Creative Medical Technology Holdings, Inc. | |
| IR@CreativeMedicalTechnology.com | |
| www.creativemedicaltechnology.com | |
| Investor Relations: | |
| Devin Sullivan, Managing Director | Dave Gentry |
| The Equity Group Inc. | RedChip Companies |
| dsullivan@equityny.com | 1-407-644-4256 |
| CELZ@redchip.com | |
| Conor Rodriguez | |
| Associate | Paul Kuntz |
| crodriguez@equityny.com | Communications Director |
| RedChip Companies | |
| paul@redchip.com | |
| 412-708-4590 | |
FAQ
What patents did Creative Medical (CELZ) receive on October 7, 2025?
What do CELZ’s new patents cover for Type 1 diabetes and heart failure?
How long is Creative Medical’s ImmCelz™ patent protection for CELZ?
Is there clinical evidence for ImmCelz™ efficacy reported by CELZ?
What patient populations does CELZ say ImmCelz™ could address?
Does CELZ link its programs to the 2025 Nobel Prize in Physiology or Medicine?
